 | • レポートコード：360iR22NB136 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、239ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療機器 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に4,550.91百万ドルであった世界の胃食道逆流症用装置市場規模が、2022年に5,159.83百万ドルになり、2027年まで年平均13.55%で成長して9,758.51百万ドルに達すると予測しています。本レポートでは、胃食道逆流症用装置の世界市場を広く調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（診断装置、食道・胃用スコープ、胃底部造襞用装置、マノメトリー装置、その他）分析、処置別（診断方法、胃底皺襞形成術、磁気括約筋増強、高周波熱アブレーション）分析、装置別（ブラボー逆流検査装置、デジトラッパー逆流検査装置、LINX逆流管理装置、MUSE–メディガス超音波外科用エンドステープラー、その他）分析、手術別（侵襲手術、非侵襲手術）分析、投与経路別（経口、非経口）分析、治療薬形状別（液体、固形）分析、エンドユーザー別（政府、病院、医師、その他）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめています。本書では、Addex Pharmaceuticals Ltd.、Aros Pharma ApS、AstraZeneca Plc、C. R. Bard, Inc.,、Eisai Co., Ltd、EndoGastric Solutions, Inc.、KARL STORZ SE & Co. KG、MediGus Ltd.、Olympus Corporation、PENTAX Medical (Global)、Pfizer Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の胃食道逆流症用装置市場規模：製品別 - 診断装置の市場規模 - 食道・胃用スコープの市場規模 - 胃底部造襞用装置の市場規模 - マノメトリー装置の市場規模 - その他の市場規模 ・世界の胃食道逆流症用装置市場規模：処置別 - 診断方法の市場規模 - 胃底皺襞形成術の市場規模 - 磁気括約筋増強の市場規模 - 高周波熱アブレーションの市場規模 ・世界の胃食道逆流症用装置市場規模：装置別 - ブラボー逆流検査装置の市場規模 - デジトラッパー逆流検査装置の市場規模 - LINX逆流管理装置の市場規模 - MUSE–メディガス超音波外科用エンドステープラーの市場規模 - その他の市場規模 ・世界の胃食道逆流症用装置市場規模：手術別 - 侵襲手術における市場規模 - 非侵襲手術における市場規模 ・世界の胃食道逆流症用装置市場規模：投与経路別 - 経口投与における市場規模 - 非経口投与における市場規模 ・世界の胃食道逆流症用装置市場規模：治療薬形状別 - 液体治療薬の市場規模 - 固形治療薬の市場規模 ・世界の胃食道逆流症用装置市場規模：エンドユーザー別 - 政府における市場規模 - 病院における市場規模 - 医師における市場規模 - その他における市場規模 ・世界の胃食道逆流症用装置市場規模：地域別 - 南北アメリカの胃食道逆流症用装置市場規模 アメリカの胃食道逆流症用装置市場規模 カナダの胃食道逆流症用装置市場規模 ブラジルの胃食道逆流症用装置市場規模 … - アジア太平洋の胃食道逆流症用装置市場規模 日本の胃食道逆流症用装置市場規模 中国の胃食道逆流症用装置市場規模 インドの胃食道逆流症用装置市場規模 韓国の胃食道逆流症用装置市場規模 台湾の胃食道逆流症用装置市場規模 … - ヨーロッパ/中東/アフリカの胃食道逆流症用装置市場規模 イギリスの胃食道逆流症用装置市場規模 ドイツの胃食道逆流症用装置市場規模 フランスの胃食道逆流症用装置市場規模 ロシアの胃食道逆流症用装置市場規模 … - その他地域の胃食道逆流症用装置市場規模 ・競争状況 ・企業情報 |
The Global Gastroesophageal Reflux Disease Devices Market size was estimated at USD 4,550.91 million in 2021 and expected to reach USD 5,159.83 million in 2022, and is projected to grow at a CAGR 13.55% to reach USD 9,758.51 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Gastroesophageal Reflux Disease Devices to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product Type, the market was studied across Diagnostic Devices, Esophagoscopes and Gastroscopes, Fundoplication Devices, Manometry System, PH Monitoring System, Radiofrequency Ablation Devices, Sphincter Augmentation Devices, Treatment Devices, and Ultrasonic Surgical Endostapler.
Based on Procedure Type, the market was studied across Diagnostic Procedures, Fundoplication Procedures, Magnetic Sphincter Augmentation, and Radiofrequency Thermal Ablation.
Based on Device Type, the market was studied across Bravo Reflux Testing System, Digitrapper reflux testing system, LINX Management System, MUSE –Medigus Ultrasonic Surgical Endostapler, Others, and Stretta Therapy.
Based on Surgery Type, the market was studied across Invasive and Non-invasive. The Invasive is further studied across Linx Reflux Management and Medigus Ultrasonic Surgical Endostapler. The Non-invasive is further studied across Endocinch Endolumminal gastroplication, Endoscopic Plicator System, EsophyX, Plexiglas poly-methyl-methacrylate (PMMA) microspheres, and Stretta.
Based on Route of Administration, the market was studied across Oral and Parenteral.
Based on Dosage Form, the market was studied across Liquid and Solid.
Based on End-User, the market was studied across Government, Hospitals, Medical Practitioners, and Others.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Gastroesophageal Reflux Disease Devices market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Gastroesophageal Reflux Disease Devices Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Gastroesophageal Reflux Disease Devices Market, including Addex Pharmaceuticals Ltd., Aros Pharma ApS, AstraZeneca Plc, C. R. Bard, Inc.,, Eisai Co., Ltd, EndoGastric Solutions, Inc., KARL STORZ SE & Co. KG, MediGus Ltd., Olympus Corporation, PENTAX Medical (Global), Pfizer Inc., Takeda Pharmaceutical Company Limited, and The Procter & Gamble Company.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Gastroesophageal Reflux Disease Devices Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gastroesophageal Reflux Disease Devices Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastroesophageal Reflux Disease Devices Market?
4. What is the competitive strategic window for opportunities in the Global Gastroesophageal Reflux Disease Devices Market?
5. What are the technology trends and regulatory frameworks in the Global Gastroesophageal Reflux Disease Devices Market?
6. What is the market share of the leading vendors in the Global Gastroesophageal Reflux Disease Devices Market?
7. What modes and strategic moves are considered suitable for entering the Global Gastroesophageal Reflux Disease Devices Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising aging population across the world
5.1.1.2. Growing obese population and their preference for surgeries
5.1.1.3. Surge in adoption among diagnostic centers and private clinics
5.1.2. Restraints
5.1.2.1. Availability of alternative such as proton pump inhibitors
5.1.3. Opportunities
5.1.3.1. Robust innovation and launch of new advanced products in the market
5.1.3.2. Ongoing trend of self-medication and awareness of the disease
5.1.4. Challenges
5.1.4.1. Decreased acceptability of devices an dearth of standard regulatory approval
5.2. Cumulative Impact of COVID-19
6. Gastroesophageal Reflux Disease Devices Market, by Product Type
6.1. Introduction
6.2. Diagnostic Devices
6.3. Esophagoscopes and Gastroscopes
6.4. Fundoplication Devices
6.5. Manometry System
6.6. PH Monitoring System
6.7. Radiofrequency Ablation Devices
6.8. Sphincter Augmentation Devices
6.9. Treatment Devices
6.10. Ultrasonic Surgical Endostapler
7. Gastroesophageal Reflux Disease Devices Market, by Procedure Type
7.1. Introduction
7.2. Diagnostic Procedures
7.3. Fundoplication Procedures
7.4. Magnetic Sphincter Augmentation
7.5. Radiofrequency Thermal Ablation
8. Gastroesophageal Reflux Disease Devices Market, by Device Type
8.1. Introduction
8.2. Bravo Reflux Testing System
8.3. Digitrapper reflux testing system
8.4. LINX Management System
8.5. MUSE –Medigus Ultrasonic Surgical Endostapler
8.6. Others
8.7. Stretta Therapy
9. Gastroesophageal Reflux Disease Devices Market, by Surgery Type
9.1. Introduction
9.2. Invasive
9.3.1. Linx Reflux Management
9.3.2. Medigus Ultrasonic Surgical Endostapler
9.3. Non-invasive
9.4.1. Endocinch Endolumminal gastroplication
9.4.2. Endoscopic Plicator System
9.4.3. EsophyX
9.4.4. Plexiglas poly-methyl-methacrylate (PMMA) microspheres
9.4.5. Stretta
10. Gastroesophageal Reflux Disease Devices Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
11. Gastroesophageal Reflux Disease Devices Market, by Dosage Form
11.1. Introduction
11.2. Liquid
11.3. Solid
12. Gastroesophageal Reflux Disease Devices Market, by End-User
12.1. Introduction
12.2. Government
12.3. Hospitals
12.4. Medical Practitioners
12.5. Others
13. Americas Gastroesophageal Reflux Disease Devices Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Gastroesophageal Reflux Disease Devices Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Gastroesophageal Reflux Disease Devices Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Addex Pharmaceuticals Ltd.
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Aros Pharma ApS
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. AstraZeneca Plc
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. C. R. Bard, Inc.,
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Eisai Co., Ltd
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. EndoGastric Solutions, Inc.
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. KARL STORZ SE & Co. KG
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. MediGus Ltd.
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. Olympus Corporation
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. PENTAX Medical (Global)
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. Pfizer Inc.
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Takeda Pharmaceutical Company Limited
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. The Procter & Gamble Company
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing